Navigation Links
Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
Date:7/23/2008

SEATTLE, July 23 /PRNewswire/ -- Sound Pharmaceuticals (SPI) has filed an Investigational New Drug Application with the FDA for the clinical testing of a proprietary formulation of ebselen for the prevention of chemotherapy induced hearing loss or ototoxicity. The oral capsule containing ebselen, SPI-3005, will be tested in advanced stage lung cancer and head and neck cancer patients receiving platinum based chemotherapy. This marks the second development program for SPI to enter clinical testing for a hearing loss indication. Last year, SPI-1005, an oral capsule containing ebselen entered Phase II testing with the US Navy for the prevention and treatment of noise induced hearing loss.

Currently there are no FDA approved drugs for the prevention and treatment of drug induced hearing loss or ototoxicity. SPI hopes to address this unmet medical need with its first in class first in indication drug. Several different research groups have shown that chemotherapy treatment reduces glutathione peroxidase (GPx) activity in the mammalian inner ear resulting in hearing loss, tinnitus, vertigo and dizziness. GPx is the dominant catalytic antioxidant enzyme within the inner ear, and a loss of its activity results in irreparable damage to hair cells, neurons and non-sensory tissues that are critical for hearing and balance. "A dose limiting side effect of platinum based chemotherapies are their devastating ototoxicity and neurotoxicity, and SPI-3005 is designed to attenuate these side effects without inhibiting the therapeutic efficacy of platinum or taxane based chemotherapies," said VP Eric Lynch, PhD.

"Otoprotectants such as SPI-3005 have the potential to reduce and/or alleviate chemotherapy-induced ototoxicity, and clinical studies should be pursued," said Stephen Fausti, PhD, and Director of the National Center for Rehabilitative Auditory Research (NCRAR) at the Portland VA, Professor of Otolaryngology and Neurology at Oregon Health Sciences University
'/>"/>

SOURCE Sound Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
2. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
3. Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer
4. Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
(Date:12/24/2014)... DUBLIN and RALEIGH, N.C. ... subsidiary of Endo International plc (NASDAQ: ENDP ... BDSI ) announced today that they have ... Buccal Film to the U.S. Food and Drug Administration ... the management of pain severe enough to require daily, ...
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... "US Self-monitoring Blood Glucose Market" report to ... This market insight focuses on the developments ... the United States . Reimbursement analysis and the ... analyses for more than 73 SMBG meters have been ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2
...   Syndax Pharmaceuticals, Inc ., a clinical-stage epigenetics oncology ... 2 clinical trials with entinostat in combination and as ... conferences.  San Antonio Breast Cancer ... randomized, double-blind, placebo-controlled, phase 2 study of exemestane with ...
...  Henry Schein, Inc., (NASDAQ: HSIC ), the ... office-based practitioners, announced today that Stanley Bergman, Chairman and ... the Company,s Executive Vice President and Chief Financial Officer, ... on December 6.  The conference is being held at ...
Cached Medicine Technology:Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 2Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 3Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 4Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 5Henry Schein to Present at the NASDAQ OMX 27th Investor Program 2
(Date:12/25/2014)... December 26, 2014 Recently, iFitDress.com, the popular ... women, has announced its new selection of black one-shoulder ... on sale now; they are available at discounted prices, up ... “The promotion will last for three weeks only. You know, ... Those who are interested in our new items can visit ...
(Date:12/25/2014)... 2014 Helen Harris’ RP (Retinitis Pigmentosa) ... California after an 8 year battle with breast cancer. ... evening in her home in Woodland Hills California after ... , As the founder and volunteer ... pioneered and championed many of today's greatest breakthroughs in ...
(Date:12/25/2014)... common during the holidays, but there are strategies that can ... arrive at a party hungry. It may seem logical to ... party, but deprivation leads to hunger, and hunger leads to ... Mount Kisco, N.Y., said in a hospital news release. ... to have a snack before attending a party when you ...
(Date:12/25/2014)... 25, 2014 “ SmileStix ” was featured ... the latest and coolest mobile applications on the iOS, Android, ... host of NewsWatch, conducted the app review and shared with ... personal stickers. , The old saying goes, “A picture says ... words that can describe a single image, because each picture ...
(Date:12/24/2014)... Wauwatosa, Wi (PRWEB) December 25, 2014 ... who are unable to afford certain items. During the holiday ... , "We collected over 70 toys," says Dr. Sara Mahalko-Leonhardt, ... myself and staff such joy, knowing that we are able ... any present had it not been for the generosity of ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2
... ... season, FORT WORTH, Texas, Nov. 13 ... Jude,during the 2008 holiday shopping season for the 5th anniversary of the,Thanks and ... RadioShack is asking customers to "Give thanks,for the healthy kids in your life, ...
... to emphasize smoking prevention for young girls has been ... Medical School (DMS). The safe, online patient education site ... prevent smoking in young girls 8-11 years old). , ... the siteNo Smoking Room.Org ( www.nosmokingroom.org ) is designed ...
... Nov. 13 NBTY, Inc. (NYSE:,NTY) (http://www.NBTY.com ), ... announced that Arthur Rudolph, its Founder,and a member of ... plan to sell a portion of his NBTY stock ... asset diversification and liquidity. The stock,trading plan was adopted ...
... (Nasdaq: AMLN ) will be presenting at the ... November,19, 2008 at 8:30 a.m. ET. Daniel M. Bradbury, ... providing a corporate overview., The live presentation will ... following the event. The Web cast and recording will ...
... $3.8 million Innovator Award, from the Department of Defense, ... renowned cancer researcher at the University of California, Santa ... is known for his innovative, interdisciplinary research. "This is ... them," said Ruoslahti. "I am very happy at being ...
... Nov. 13 Debiopharm Group,(Debiopharm), a global ... conditions and particularly oncology, today,announced that the ... month formulation,of Trelstar(R) (triptorelin pamoate) has been ... Food and Drug Administration (FDA). Trelstar(R) is ...
Cached Medicine News:Health News:RadioShack Partners With St. Jude Children's Research Hospital(R) on the 5th Anniversary of the Thanks and Giving(R) Campaign 2Health News:RadioShack Partners With St. Jude Children's Research Hospital(R) on the 5th Anniversary of the Thanks and Giving(R) Campaign 3Health News:Innovative new Web site empowers young girls to live smoke-free 2Health News:NBTY Founder Adopts Rule 10b5-1 Trading Plan 2Health News:Cancer researcher receives $3.8 million award from US Department of Defense 2Health News:Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer 2
DCR Set, Angled....
... The Leica CM3050 S Cryostat ... with excellent safety standards for ... applications. The Leica CM3050 S ... for all cryosectioning research applications ...
... The Bright 7500 is a freestanding ... liquid decontamination system and a radial ... to cut a wide range of ... effective for use in high biohazard ...
... - a vision becomes reality. Numerous ... the users many benefits.,The Cryo-Star is ... retraction that incorporates a unique refrigeration ... cooling. This facilitates applications in both ...
Medicine Products: